MediPrint Ophthalmics Adds HA-Eluting Contact Lens to Pipeline

MediPrint Ophthalmics announced March 5 that it would expand its clinical program to address contact lens dropout due to discomfort with a drug-eluting contact lens that continuously delivers hyaluronic acid (HA).

MediPrint (formerly Leo Lens), of San Diego, California, set glaucoma as its initial therapeutic target. In a clinical study of its bimatoprost-eluting contact lenses, which incorporated sustained HA delivery, patients reported a 38 percent improvement in comfort and a 40 percent reduction in dry eye symptoms.

“By expanding into the broader contact lens market, we aim to recapture the significant portion of patients who have abandoned lenses due to discomfort,” said Praful Doshi, MediPrint founder and CEO.

MediPrint said it plans to develop its comfort-enhancing technology for use in both daily and weekly disposable lenses. The company’s website indicates that it will pursue the US FDA’s 510(k) regulatory pathway.